The mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024. Preclinical program data to be presented at the 2023 Hep DART Conference .

Glox Therapeutics, announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Range of highly selective anti-idiotypic antibodies now includes six antibodies specific to dupilumab and its biosimilars for bioanalysis and Drug Monitoring.

AMSBIO has supplied a custom monoclonal antibody (mAB) to researchers at the TU Dortmund** in Germany to unravel the role of EDI3 in breast cancer development.

Lateral flow test enables Botrytis concentration to be measured in grape must and in finished wine, in addition to monitoring in the vineyard.

New ready-to-ship xGen™ NGS solution will enable researchers to combat challenging diseases of today and prepare for the next pathogen of tomorrow.

Absolute Biotech has announced the reintroduction of SCICONS™ dsRNA antibodies, used to detect dsRNA intermediates of a wide range of viruses, including chikungunya, dengue, hepatitis, rabies, rhinovirus, polio and swine fever.

The Center for Emerging Viral Threats (CEVT) in Louisiana, USA, is using INTEGRA Biosciences’ liquid handling solutions for COVID-19 testing and viral genomics studies.

Cherwell has published findings of a new impartial investigation into the impact of using pre-poured Petri dishes from different suppliers for air sampling in cleanroom environmental monitoring programs.

A new clinical trial of a ground-breaking phage-based molecular diagnostic, has been agreed. The trial is aimed at evaluating the performance of the phage assay as a first-line blood-based diagnostic for active pulmonary Tuberculosis.